Klein, Sebastian
Tolkach, Yuri
Reinhardt, Hans Christian
Buettner, Reinhard
Quaas, Alexander
Helbig, Doris
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 26 June 2023
Accepted: 22 May 2024
First Online: 31 May 2024
Competing interests
: R.B. received consulting and lecture fees from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Illumina, Lilly, Merck-Serono, MSD, Novartis, Qiagen, Pfizer, Roche, Targos MP Inc. R.B. is Co-Founder and Scientific Advisor for Targos Mol. Pathology Inc and member of the Directory Board Gnothis Inc. H.C.R. (Hans Christian Reinhardt) received consulting and lecture fees from Abbvie, Astra Zeneca, Roche, Novartis, Vertex and Merck. H.C.R. received research funding from Gilead Pharmaceuticals and Astra Zeneca. H.C.R. is a co-founder of CDL Therapeutics GmbH. The remaining authors state no conflict of interest.